Goldman Sachs Group Inc. raised its position in Cascadian Therapeutics, Inc. (NASDAQ:CASC) by 920.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,178 shares of the biopharmaceutical company’s stock after buying an additional 185,081 shares during the period. Goldman Sachs Group Inc.’s holdings in Cascadian Therapeutics were worth $849,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of CASC. BlueCrest Capital Management Ltd purchased a new stake in shares of Cascadian Therapeutics during the first quarter worth $122,000. Bank of America Corp DE raised its stake in shares of Cascadian Therapeutics by 2,316.5% in the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 35,975 shares during the period. Sabby Management LLC purchased a new stake in shares of Cascadian Therapeutics during the first quarter worth $669,000. Citadel Advisors LLC purchased a new stake in shares of Cascadian Therapeutics during the first quarter worth $142,000. Finally, Geode Capital Management LLC raised its stake in shares of Cascadian Therapeutics by 118.8% in the first quarter. Geode Capital Management LLC now owns 252,934 shares of the biopharmaceutical company’s stock worth $1,047,000 after buying an additional 137,350 shares during the period. 83.86% of the stock is owned by hedge funds and other institutional investors.

Shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) traded up 1.08% on Tuesday, hitting $3.73. The stock had a trading volume of 25,580 shares. The stock has a 50 day moving average of $3.92 and a 200 day moving average of $4.02. Cascadian Therapeutics, Inc. has a 12-month low of $3.18 and a 12-month high of $10.98. The firm’s market cap is $188.56 million.

Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. During the same period last year, the firm earned ($1.57) earnings per share. Equities analysts predict that Cascadian Therapeutics, Inc. will post $5.02 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Cascadian Therapeutics, Inc. (CASC) Shares Bought by Goldman Sachs Group Inc.” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/cascadian-therapeutics-inc-casc-shares-bought-by-goldman-sachs-group-inc/1491058.html.

A number of brokerages have weighed in on CASC. BTIG Research began coverage on Cascadian Therapeutics in a research report on Friday, April 21st. They set a “buy” rating for the company. Cowen and Company reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research report on Wednesday, August 9th. Zacks Investment Research downgraded Cascadian Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Cantor Fitzgerald reiterated a “hold” rating and issued a $4.00 price target on shares of Cascadian Therapeutics in a report on Wednesday, May 10th. Finally, ValuEngine downgraded Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.17.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Want to see what other hedge funds are holding CASC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cascadian Therapeutics, Inc. (NASDAQ:CASC).

Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.